[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-353230-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-353230-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","a-novel-combination-therapy-for-er-breast-cancer-suppresses-drug-resistance-via-an-evolutionary-double-bind","A novel combination therapy for ER+ breast cancer suppresses drug resistance via an evolutionary double-bind","","Chemotherapy is widely used for metastatic ER+ breast cancer, yet many patients develop resistance that drives progression. The study proposes an “evolutionary double-bind,” where adaptation to one treatment increases susceptibility to another, leveraging vulnerabilities arising during acquired resistance. Using ER+ breast cancer spheroid lineages with varied initial population frequencies, the work quantifies cross-sensitivity and evaluates add-on therapies such as disulfiram across dosing schedules. A game-theoretic model parameterized from in vitro data predicts double-bind behavior and dose-dependent re-sensitization to chemotherapy.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/a-novel-combination-therapy-for-er-breast-cancer-suppresses-drug-resistance-via-an-evolutionary-double-bind/353230/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/a-novel-combination-therapy-for-er-breast-cancer-suppresses-drug-resistance-via-an-evolutionary-double-bind/353230.png","ImageObject",300,407,{"name":42,"@type":43},"Well Done","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-24","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the “evolutionary double-bind” hypothesis in this study?","Question",{"text":63,"@type":64},"Adapting to one treatment is proposed to make cancer cells more susceptible to a second treatment. This targets vulnerabilities that emerge from acquired resistance mechanisms.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How are cross-sensitivity and add-on treatment effects measured?",{"text":68,"@type":64},"ER+ breast cancer cell lineages, including chemotherapy-sensitive and -resistant variants, are grown in spheroids with varied initial population frequencies. Different treatment schedules are tested to reduce selection of resistant populations.",{"name":70,"@type":61,"acceptedAnswer":71},"What modeling approach is used to predict the double-bind?",{"text":72,"@type":64},"The authors develop a game-theoretic mathematical model parameterized from in vitro experimental data. The model predicts that resistance selection to chemotherapy induces sensitivity to disulﬁram and can restore chemotherapy response in a dose-dependent manner.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},353230,1791223120,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},5909892210082,"https://ap-avatar.wpscdn.com/avatar/56001069da27c9f41e8?x-image-process=image/resize,m_fixed,w_180,h_180&k=1789614185077863061","Article  \nA novel combination therapy for ER+ breast cancer suppresses drug resistance via an evolutionary double-bind  \nRena Emond 1, Jeffrey West 2, Vince K Grolmusz 1, Patrick A Cosgrove 1, Aritro Nath1, Alexander R A Anderson 2 ✉ & Andrea H Bild 1 ✉  \nAbstract  \nChemotherapy remains a commonly used and important treatment option for metastatic breast cancer. A majority of Estrogen Receptor-positive (ER + ) metastatic breast cancer patients ultimately develop resistance to chemotherapy, resulting in disease progression. We hypothesized that an “evolutionary double-bind”, where adapting to one treatment inadvertently makes cancer cells more susceptible to another treatment, would improve the effectiveness and durability of response to chemotherapy. This approach exploits vulnerabilities in acquired resistance mechanisms. Evolutionary models can be used to identify alternative treatment strategies that capitalize on such vulnerabilities in refractory cancers, leading to improved outcomes. To develop and test these models, ER+ breast cancer cell lineages sensitive and resistant to chemotherapy were grown in spheroids with varied initial population frequencies to measure cross-sensitivity andefﬁcacy of chemotherapy and add-on treatments, such as disulﬁram. Different treatment schedules were evaluated to identify the most effective strategy for reducing the selection of resistant populations, thereby preventing their proliferation and dominance. We developed a game-theoretic mathematical model, parameterized from this in vitro experimental data, and used it to predict the existence of a double-bind, where selection for resistance to chemotherapy induces sensitivity to disulﬁram. The model predicts a dose-dependent re-sensitization to chemotherapy formonotherapy disulﬁram.  \nKeywords Disulﬁram; Organoid; Chemotherapy Resistance; Evolutionary Game Theory; Mathematical Modeling  \nSubject Category Cancer  \n[https://doi.org/10.1038/s44320-026-00191-z](https://doi.org/10.1038/s44320-026-00191-z)  \nReceived 10 January 2025; Revised 3 December 2025; Accepted 13 January 2026  \nPublished online: 26 March 2026  \nIntroduction  \nIdentifying two drugs with synergistic action when combined is a promising strategy to combat drug resistance. While combination treatments have shown clinical promise (Wang and Minden, 2022), analytical methods to optimize treatment response remain limited due to heterogeneous response, multi-drug resistance, multiple resistance mechanisms, or simply a lack of available drugs that qualify as synergistic (Tufail et al, 2022; Ji et al, 2019) . In this work, we implement a drug screening strategy in breast cancer that quantiﬁes the presence of drug synergy in parental and evolved resistance breast cancer cell lines to develop new analysis methods for the assessment of combination therapy effectiveness. Importantly, this new analysis method also considers the potential for heterogeneous cell–cell interactions to negate (or promote) any drug synergy that is present. Here, we apply this screening process to identify effective chemotherapy add-on treatments in breast cancer cell lines. The goal of this drug screen is to identify a candidate drug that can be classiﬁed as an “evolutionary doublebind,” whereby the mechanism of resistance for a ﬁrst-line therapy induces a vulnerability to this candidate second-line treatment (Basanta et al, 2011, 2012a; Gatenby et al, 2009a) .  \nDrug combinations can be classiﬁed as additive (neutral), synergistic, or antagonistic. Identifying candidate drugs that are collaterally sensitive to ﬁrst-line treatments represents a promising strategy to mitigate treatment resistance in antibiotics (Aulin et al, 2021; Nichol et al, 2019) and cancer (Dhawan et al, 2017) . Collateral sensitivity is deﬁned as the increased susceptibility to a particular drug when resistance to a separate drug has increased. Collateral sensitivity is often quantiﬁed using comprehensive multidose drug response assays, ap","cbCaipq6rYOMANHu","https://ap.wps.com/l/cbCaipq6rYOMANHu","pdf",6610591,27,"English","# Introduction\n## Drug synergy and optimization\n## Collateral sensitivity and evolved resistance\n## Limits of screening methods\n# Theoretical basis: cell–cell interactions","[{\"question\":\"What is the “evolutionary double-bind” hypothesis in this study?\",\"answer\":\"Adapting to one treatment is proposed to make cancer cells more susceptible to a second treatment. This targets vulnerabilities that emerge from acquired resistance mechanisms.\"},{\"question\":\"How are cross-sensitivity and add-on treatment effects measured?\",\"answer\":\"ER+ breast cancer cell lineages, including chemotherapy-sensitive and -resistant variants, are grown in spheroids with varied initial population frequencies. Different treatment schedules are tested to reduce selection of resistant populations.\"},{\"question\":\"What modeling approach is used to predict the double-bind?\",\"answer\":\"The authors develop a game-theoretic mathematical model parameterized from in vitro experimental data. The model predicts that resistance selection to chemotherapy induces sensitivity to disulﬁram and can restore chemotherapy response in a dose-dependent manner.\"}]","A novel combination therapy for ER+ breast cancer suppresses drug resistance via an evolutionary double-bind | PDF",1790103713,68,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/74f54c6cb5f05ac680edda4687f4f560.webp",983,1305,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3d2b7378bdb8c1885b48501aedac0f1f.webp",982,1304,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c09c8ade29812036e904682d2a24ec4c.webp",981,1303,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1dd043a54d8b66974bd13917ade2e2b6.webp",980,1301]